||
利用汤森路透科技集团的基本科学指标库(Essential Science Indicators)2004-2010间的高被引论文及其同被引聚类分析,通过同被引而密切关联的相关论文聚类形成若干个科学研究领域,由此绘制科学文献所反映的科学研究结构地图,讨论科学发展的基本格局。通过研究和揭示科学结构及其演化,为各领域研究提供一种思考问题、发现潜在交叉学科、“热点”领域。
RA的名称 | HIV感染的治疗
| RA ID | 88 | |
RA的关键词 | immunodeficiency virus type; human immunodeficiency virus; human immunodeficiency virus type; immunodeficiency virus; virus type; antiretroviral therapy; human immunodeficiency; anti-human immunodeficiency virus type; antiretroviral therapy in; highly active antiretroviral therapy | |||
包含RF数(Hot RF数) | 核心论文数 | 去重被引次数 | 总被引次数 | 平均出版年 |
9(2) | 95 | 3970 | 7471 | 2004.5 |
该RA中包含RF的图谱 | ||||
RF ID | 核心论文数 | 去重被引次数 | 总被引次数 | 平均出版年 | 是否为热点 |
7281 | 31 | 1188 | 3146 | 2004.7 | No |
RF的关键词 | broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2g12; human immunodeficiency virus type 1 glycoprotein gp120; acute human immunodeficiency virus type 1 subtype c infection |
论文题目 | 被引 | 年份 | 刊名 | 卷 | 期 | 第一作者 |
antibody neutralization and escape by hiv-1
| 449 | 2003 | NATURE | 422 | 6929 | WEI XP |
rapid evolution of the neutralizing antibody response to hiv type 1 infection
| 249 | 2003 | PROC NAT ACAD SCI USA | 100 | 7 | RICHMAN DD |
the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2g12 recognizes a cluster of alpha 1 -> 2 mannose residues on the outer face of gp120
| 199 | 2002 | J VIROL | 76 | 14 | SCANLAN CN |
carbohydrate arrays for the evaluation of protein binding and enzymatic modification
| 192 | 2002 | CHEM BIOL | 9 | 4 | HOUSEMAN BT |
antibody domain exchange is an immunological solution to carbohydrate cluster recognition
| 166 | 2003 | SCIENCE | 300 | 5628 | CALARESE DA |
the mannose-dependent epitope for neutralizing antibody 2g12 on human immunodeficiency virus type 1 glycoprotein gp120
| 165 | 2002 | J VIROL | 76 | 14 | SANDERS RW |
oligosaccharide microarrays for high-throughput detection and specificity assignments of carbohydrate-protein interactions
| 144 | 2002 | NAT BIOTECHNOL | 20 | 10 | FUKUI S |
comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
| 141 | 2004 | J VIROL | 78 | 23 | BINLEY JA |
printed covalent glycan array for ligand profiling of diverse glycan binding proteins
| 136 | 2004 | PROC NAT ACAD SCI USA | 101 | 49 | BLIXT O |
structure of an unliganded simian immunodeficiency virus gp120 core
| 128 | 2005 | NATURE | 433 | 7028 | CHEN B |
envelope-constrained neutralization-sensitive hiv-1 after heterosexual transmission
| 107 | 2004 | SCIENCE | 303 | 5666 | DERDEYN CA |
maleimide-functionalized self-assembled monolayers for the preparation of peptide and carbohydrate biochips
| 96 | 2003 | LANGMUIR | 19 | 5 | HOUSEMAN BT |
human immunodeficiency virus type 1 env clones from acute and early subtype b infections for standardized assessments of vaccine-elicited neutralizing antibodies
| 94 | 2005 | J VIROL | 79 | 16 | LI M |
delay of hiv-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
| 90 | 2005 | NATURE MED | 11 | 6 | TRKOLA A |
structure of a v3-containing hiv-1 gp120 core
| 87 | 2005 | SCIENCE | 310 | 5750 | HUANG CC |
cardiolipin polyspecific autoreactivity in two broadly neutralizing hiv-1 antibodies
| 86 | 2005 | SCIENCE | 308 | 5730 | HAYNES BF |
structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2f5 in complex with its gp41 epitope
| 81 | 2004 | J VIROL | 78 | 19 | OFEK G |
distribution and three-dimensional structure of aids virus envelope spikes
| 68 | 2006 | NATURE | 441 | 7095 | ZHU P |
carbohydrate chips for studying high-throughput carbohydrate-protein interactions
| 64 | 2004 | J AM CHEM SOC | 126 | 15 | PARK S |
the use of carbohydrate microarrays to study carbohydrate-cell interactions and to detect pathogens
| 63 | 2004 | CHEM BIOL | 11 | 12 | DISNEY MD |
gp120: target for neutralizing hiv-1 antibodies
| 57 | 2006 | ANNU REV IMMUNOL | 24 |
| PANTOPHLET R |
structural definition of a conserved neutralization epitope on hiv-1 gp120
| 47 | 2007 | NATURE | 445 | 7129 | ZHOU TQ |
dissection of the carbohydrate specificity of the broadly neutralizing-anti-hiv-1 antibody 2g12
| 46 | 2005 | PROC NAT ACAD SCI USA | 102 | 38 | CALARESE DA |
carbohydrate microarrays: an advanced technology for functional studies of glycans
| 46 | 2005 | CHEM-EUR J | 11 | 10 | SHIN I |
neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent hiv infection
| 44 | 2005 | PROC NAT ACAD SCI USA | 102 | 51 | FROST SDW |
microarrays of synthetic heparin oligosaccharides
| 31 | 2006 | J AM CHEM SOC | 128 | 9 | DE PAZ JL |
carbohydrate microarray for profiling the antibodies interacting with globo h tumor antigen
| 27 | 2006 | PROC NAT ACAD SCI USA | 103 | 1 | HUANG CY |
neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype c infection
| 12 | 2007 | J VIROL | 81 | 12 | GRAY ES |
antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a dna prime-protein boost immunization strategy
| 11 | 2007 | J VIROL | 81 | 8 | LAW M |
cross-reactive hiv-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (r2) with broadly hiv-1 neutralizing antibodies
| 11 | 2007 | VIROLOGY | 363 | 1 | CHOUDHRY V |
rational modifications of hiv-1 envelope glycoproteins for immunogen design
| 9 | 2007 | CURR PHARM DESIGN | 13 | 2 | PHOGAT S |
RF ID | 核心论文数 | 去重被引次数 | 总被引次数 | 平均出版年 | 是否为热点 |
6534 | 22 | 382 | 1142 | 2005.6 | No |
RF的关键词 | human immunodeficiency virus type 1 coreceptor tropism; human immunodeficiency virus type 1 coreceptor switching; cxcr4-using human immunodeficiency virus type 1 (hiv-1) variants; novel hiv-1 integrase inhibitors |
论文题目 | 被引 | 年份 | 刊名 | 卷 | 期 | 第一作者 |
integrase inhibitors to treat hiv/aids
| 122 | 2005 | NAT REV DRUG DISCOV | 4 | 3 | POMMIER Y |
diketo acid inhibitor mechanism and hiv-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes
| 110 | 2002 | PROC NAT ACAD SCI USA | 99 | 10 | GROBLER JA |
integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques
| 92 | 2004 | SCIENCE | 305 | 5683 | HAZUDA DJ |
efficacy of short-term monotherapy with maraviroc, a new ccr5 antagonist, in patients infected with hiv-1
| 87 | 2005 | NATURE MED | 11 | 11 | FATKENHEUER G |
design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of hiv-1 integrase in vitro and in infected cells
| 86 | 2003 | J MED CHEM | 46 | 4 | ZHUANG LC |
maraviroc (uk-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor ccr5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
| 74 | 2005 | ANTIMICROB AGENTS CHEMOTHER | 49 | 11 | DORR P |
a naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of hiv-1 integrase
| 72 | 2004 | PROC NAT ACAD SCI USA | 101 | 31 | HAZUDA DJ |
ccr5 deficiency increases risk of symptomatic west nile virus infection
| 63 | 2006 | J EXP MED | 203 | 1 | GLASS WG |
durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced hiv-1-infected patients at 48 weeks in the randomized evaluation of strategic intervention in multi-drug...
| 58 | 2006 | LANCET | 368 | 9534 | HICKS CB |
the ccr5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive hiv entry inhibitor
| 55 | 2005 | MOL PHARMACOL | 67 | 4 | WATSON C |
antiretroviral activity, pharmacokinetics, and tolerability of mk-0518, a novel inhibitor of hiv-1 integrase, dosed as monotherapy for 10 days in treatment-naive hiv-1-infected individuals
| 41 | 2006 | JAIDS | 43 | 5 | MARKOWITZ M |
efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with hiv-1 infection in power 1 and 2: a pooled subgroup analysis of data from two randomised trials
| 37 | 2007 | LANCET | 369 | 9568 | CLOTET B |
emergence of cxcr4-using human immunodeficiency virus type 1 (hiv-1) variants in a minority of hiv-1-infected patients following treatment with the ccr5 antagonist maraviroc is from a pretreatment cxcr4-using virus reservoir
| 36 | 2006 | J VIROL | 80 | 10 | WESTBY M |
safety and efficacy of the hiv-1 integrase inhibitor raltegravir (mk-0518) in treatment-experienced patients with multidrug-resistant virus: a phase ii randomised controlled trial
| 33 | 2007 | LANCET | 369 | 9569 | GRINSZTEJN B |
efficacy and safety of tmc114/ritonavir in treatment-experienced hiv patients: 24-week results of power 1
| 33 | 2007 | AIDS | 21 | 4 | KATLAMA C |
human immunodeficiency virus type 1 coreceptor switching: v1/v2 gain-of-fitness mutations compensate for v3 loss-of-fitness mutations
| 32 | 2006 | J VIROL | 80 | 2 | PASTORE C |
novel hiv-1 integrase inhibitors derived from quinolone antibiotics
| 27 | 2006 | J MED CHEM | 49 | 5 | SATO M |
hiv type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a ccr5 inhibitor: aids clinical trial group a5211
| 22 | 2007 | CLIN INFECT DIS | 44 | 4 | WILKIN TJ |
phase 2 study of the safety and efficacy of vicriviroc, a ccr5 inhibitor, in hiv-1-infected, treatment experienced patients: aids clinical trials group 5211
| 19 | 2007 | J INFEC DIS | 196 | 2 | GULICK RM |
development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism
| 15 | 2007 | ANTIMICROB AGENTS CHEMOTHER | 51 | 2 | WHITCOMB JM |
the hunt for hiv-1 integrase inhibitors
| 15 | 2006 | AIDS PATIENT CARE STDS | 20 | 7 | LATAILLADE M |
efficacy and safety of tmc125 (etravirine) in treatment-experienced hiv-1-infected patients in duet-2: 24-week results from a randomised, double-blind, placebo-controlled trial
| 13 | 2007 | LANCET | 370 | 9581 | LAZZARIN A |
RF ID | 核心论文数 | 去重被引次数 | 总被引次数 | 平均出版年 | 是否为热点 |
6501 | 12 | 673 | 1964 | 2003.3 | Yes |
RF的关键词 | human immunodeficiency virus (hiv)-infected adults receiving antiretroviral therapy; human immunodeficiency virus infection; cardiovascular disease risk factors; randomized double-blind placebo-controlled study; cardiovascular risk |
论文题目 | 被引 | 年份 | 刊名 | 卷 | 期 | 第一作者 |
combination antiretroviral therapy and the risk of myocardial infarction
| 386 | 2003 | N ENGL J MED | 349 | 21 | FRIIS-MOLLER N |
cardiovascular disease risk factors in hiv patients - association with antiretroviral therapy. results from the dad study
| 186 | 2003 | AIDS | 17 | 8 | FRIIS-MOLLER N |
cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection
| 183 | 2003 | N ENGL J MED | 348 | 8 | BOZZETTE SA |
medical progress - cardiovascular risk and body-fat abnormalities in hiv-infected adults.
| 173 | 2005 | N ENGL J MED | 352 | 1 | GRINSPOON S |
an objective case definition of lipodystrophy in hiv-infected adults: a case-control study
| 165 | 2003 | LANCET | 361 | 9359 | CARR A |
abacavir substitution for nucleoside analogs in patients with hiv lipoatrophy - a randomized trial
| 153 | 2002 | JAMA-J AM MED ASSN | 288 | 2 | CARR A |
protease inhibitors and cardiovascular outcomes in patients with hiv-1
| 152 | 2002 | LANCET | 360 | 9347 | HOLMBERG SD |
increased risk of myocardial infarction with duration of protease inhibitor therapy in hiv-infected men
| 144 | 2003 | AIDS | 17 | 17 | MARY-KRAUSE M |
guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (hiv)-infected adults receiving antiretroviral therapy: recommendations of the hiv medicine association of the infectious disease society of america and the
| 138 | 2003 | CLIN INFECT DIS | 37 | 5 | DUBE MP |
substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection
| 129 | 2003 | N ENGL J MED | 349 | 11 | MARTINEZ E |
no effect of rosiglitazone for treatment of hiv-1 lipoatrophy: randomised, double-blind, placebo-controlled trial
| 90 | 2004 | LANCET | 363 | 9407 | CARR A |
rosiglitazone in the treatment of haart-associated lipodystrophy - a randomized double-blind placebo-controlled study
| 65 | 2003 | ANTIVIR THER | 8 | 3 | SUTINEN J |
RF ID | 核心论文数 | 去重被引次数 | 总被引次数 | 平均出版年 | 是否为热点 |
8131 | 8 | 629 | 1438 | 2004.5 | No |
RF的关键词 | adult hiv infection; hiv-1 infection; initial treatment; initial therapy; tenofovir df |
论文题目 | 被引 | 年份 | 刊名 | 卷 | 期 | 第一作者 |
efficacy and safety of tenofovir df vs stavuldine in combination therapy in antiretroviral-naive patients - a 3-year randomized trial
| 317 | 2004 | JAMA-J AM MED ASSN | 292 | 2 | GALLANT JE |
lopinavir-ritonavir versus nelfinavir for the initial treatment of hiv infection
| 274 | 2002 | N ENGL J MED | 346 | 26 | WALMSLEY S |
treatment for adult hiv infection - 2006 recommendations of the international aids society-usa panel
| 207 | 2006 | JAMA-J AM MED ASSN | 296 | 7 | HAMMER SM |
comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2nn study
| 176 | 2004 | LANCET | 363 | 9417 | VAN LETH F |
triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of hiv-1 infection
| 166 | 2004 | N ENGL J MED | 350 | 18 | GULICK RM |
comparison of sequential three-drug regimens as initial therapy for hiv-1 infection
| 143 | 2003 | N ENGL J MED | 349 | 24 | ROBBINS GK |
tenofovir df, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for hiv
| 134 | 2006 | N ENGL J MED | 354 | 3 | GALLANT JE |
tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in anti retroviral-naive patients - virologic, immunologic, and morphologic changes - a 96-week analysis
| 21 | 2006 | JAIDS | 43 | 5 | POZNIAK AL |
RF ID | 核心论文数 | 去重被引次数 | 总被引次数 | 平均出版年 | 是否为热点 |
9997 | 5 | 565 | 1051 | 2003.4 | Yes |
RF的关键词 | recently hiv infected patient antiretroviral drug resistance; primary hiv-1 drug resistance; recently infected persons; drug-resistant hiv-1 variants |
论文题目 | 被引 | 年份 | 刊名 | 卷 | 期 | 第一作者 |
antiretroviral-drug resistance among patients recently infected with hiv
| 437 | 2002 | N ENGL J MED | 347 | 6 | LITTLE SJ |
antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an international aids society-usa panel
| 276 | 2003 | CLIN INFECT DIS | 37 | 1 | HIRSCH MS |
time trends in primary hiv-1 drug resistance among recently infected persons
| 186 | 2002 | JAMA-J AM MED ASSN | 288 | 2 | GRANT RM |
prevalence of drug-resistant hiv-1 variants in untreated individuals in europe: implications for clinical management
| 88 | 2005 | J INFEC DIS | 192 | 6 | WENSING AMJ |
infection with multidrug resistant, dual-tropic hiv-1 and rapid progression to aids: a case report
| 64 | 2005 | LANCET | 365 | 9464 | MARKOWITZ M |
RF ID | 核心论文数 | 去重被引次数 | 总被引次数 | 平均出版年 | 是否为热点 |
10691 | 5 | 536 | 975 | 2003.2 | No |
RF的关键词 | hiv-1-infected patients starting highly active antiretroviral therapy; start highly active antiretroviral therapy; initiating antiretroviral therapy; potent antiretroviral therapy; different cd4(+) cell strata |
论文题目 | 被引 | 年份 | 刊名 | 卷 | 期 | 第一作者 |
prognosis of hiv-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
| 384 | 2002 | LANCET | 360 | 9327 | EGGER M |
decline in the aids and death rates in the eurosida study: an observational study
| 288 | 2003 | LANCET | 362 | 9377 | MOCROFT A |
survival benefit of initiating antiretroviral therapy in hiv-infected persons in different cd4(+) cell strata
| 118 | 2003 | ANN INTERN MED | 138 | 8 | PALELLA FJ |
effect of medication adherence on survival of hiv-infected adults who start highly active antiretroviral therapy when the cd4(+) cell count is 0.200 to 0.350 x 10(9) cells/l
| 106 | 2003 | ANN INTERN MED | 139 | 10 | WOOD E |
long-term effectiveness of potent antiretroviral therapy in preventing aids and death: a prospective cohort study
| 79 | 2005 | LANCET | 366 | 9483 | STERNE JAC |
RF ID | 核心论文数 | 去重被引次数 | 总被引次数 | 平均出版年 | 是否为热点 |
12225 | 5 | 529 | 1107 | 2002.8 | No |
RF的关键词 | hiv-1 fusion inhibitor efficacy; patients receiving fusion inhibitor (t-20) monotherapy; entry inhibitors correlates; drug-resistant hiv-1; fusion kinetics |
论文题目 | 被引 | 年份 | 刊名 | 卷 | 期 | 第一作者 |
enfuvirtide, an hiv-1 fusion inhibitor, for drug-resistant hiv infection in north and south america
| 294 | 2003 | N ENGL J MED | 348 | 22 | LALEZARI JP |
emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (t-20) monotherapy
| 273 | 2002 | ANTIMICROB AGENTS CHEMOTHER | 46 | 6 | WEI XP |
efficacy of enfuvirtide in patients infected with drug-resistant hiv-1 in europe and australia
| 266 | 2003 | N ENGL J MED | 348 | 22 | LAZZARIN A |
sensitivity of hiv-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
| 165 | 2002 | PROC NAT ACAD SCI USA | 99 | 25 | REEVES JD |
the entry of entry inhibitors: a fusion of science and medicine
| 109 | 2003 | PROC NAT ACAD SCI USA | 100 | 19 | MOORE JP |
RF ID | 核心论文数 | 去重被引次数 | 总被引次数 | 平均出版年 | 是否为热点 |
7635 | 4 | 95 | 215 | 2006.0 | No |
RF的关键词 | highly active antiretroviral therapy; primary care sites; rural district; high-income countries; effectiveness assessment |
论文题目 | 被引 | 年份 | 刊名 | 卷 | 期 | 第一作者 |
mortality of hiv-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries
| 94 | 2006 | LANCET | 367 | 9513 | BRAITSTEIN P |
scaling up of highly active antiretroviral therapy in a rural district of malawi: an effectiveness assessment
| 45 | 2006 | LANCET | 367 | 9519 | FERRADINI L |
rapid scale-up of antiretroviral therapy at primary care sites in zambia - feasibility and early outcomes
| 42 | 2006 | JAMA-J AM MED ASSN | 296 | 7 | STRINGER JSA |
adherence to antiretroviral therapy in sub-saharan africa and north america - a meta-analysis
| 34 | 2006 | JAMA-J AM MED ASSN | 296 | 6 | MILLS EJ |
RF ID | 核心论文数 | 去重被引次数 | 总被引次数 | 平均出版年 | 是否为热点 |
14236 | 3 | 54 | 165 | 2006.3 | No |
RF的关键词 | antiretroviral treatment cd4+count-guided interruption; cd4-guided scheduled treatment interruptions compared; antiretroviral drugs; staccato randomised trial |
论文题目 | 被引 | 年份 | 刊名 | 卷 | 期 | 第一作者 |
cd4+count-guided interruption of antiretroviral treatment
| 86 | 2006 | N ENGL J MED | 355 | 22 | EL-SADR WM |
class of antiretroviral drugs and the risk of myocardial infarction
| 44 | 2007 | N ENGL J MED | 356 | 17 | FRIIS-MOLLER N |
cd4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with hiv-1: results of the staccato randomised trial
| 35 | 2006 | LANCET | 368 | 9534 | ANANWORANICH J |
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-9-23 11:51
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社